The FDA has declined to approve Vanda Pharma's tradipitant for delayed ... key experts in the field and not appropriate based on the scientific understanding and natural course of the disorder." ...
Hosted on MSN1mon
Vanda Pharmaceuticals targets $1B revenue by 2030 with expanded psychiatry portfolioCEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% year-over-year. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback